锡类散治疗溃疡性结肠炎的系统评价  

Xilei Powder for Treatment of Ulcerative Colitis:A Systematic Evaluation

作　　者：崔德军[1] 黄国美[1] 刘哲[2] 杨大平[1] 

机构地区：[1]贵州省人民医院消化内科,贵州省贵阳市550002 [2]贵州省人民医院内镜科,贵州省贵阳市550002

出　　处：《中国全科医学》2012年第31期3631-3633,共3页Chinese General Practice

基　　金：贵州省科学技术基金〔黔科合J字(2012)2233号〕

摘　　要：目的评价锡类散治疗溃疡性结肠炎(UC)的疗效和安全性。方法采用关键词或主题词检索MED-LINE、EMBASE、Cochrane图书馆、ISI数据库、中国期刊全文数据库、中国生物医学文献数据库、中文科技期刊数据库、万方数据库以获得相关随机对照试验,检索时间从建库至2012年3月。根据纳入和排除标准由两名研究者独立进行文献质量评价,应用Review Manager 4.2.10统计软件分析疗效和安全性。效应量为相对危险度(RR)。结果根据纳入标准纳入2个比较锡类散与美沙拉嗪的随机对照试验。对照组和试验组临床缓解率间差异无统计学意义〔RR=0.97,95%CI(0.70,1.35),P>0.05〕。两组不良反应发生率间差异亦无统计学意义〔RR=0.14,95%CI(0.02,1.09),P>0.05〕。结论锡类散对UC的疗效和安全性与美沙拉嗪相当。低成本的锡类散为UC治疗提供新的有效选择。Objective To evaluate the efficacy and safety of Xilei powder on ulcerative colitis（UC）.Methods Keyword and subject heading searches of MEDLINE,EMBASE,the Cochrane Database,Science Citation Index,full-text database of chinese journals,the Chinese Biomedical Database,the database of chinese science journals and Wanfang database from the inception of each database to March 2012 were used to identify all available randomised controlled trials.Two reviewers assessed the studies independently based on the criteria of inclusion and exclusion.The statistical software Review Manager 4.2.10 was taken to estimate the effects and safety.The effect size was relative risks（RR）.Results Two randomized controlled trials comparing Xilei powder with mesalazine were qualified for the meta-analysis according to inclusion criteria.There were no statistically significant difference in clinical remission rate between control and trial groups〔RR = 0.97,95% CI（0.70,1.35）,P 0.05〕.There was no statistically significant difference between Xilei powder and mesalazine in adverse events rates 〔RR =0.14,95% CI（0.02,1.09）,P 0.05〕.Conclusion Xilei powder and mesalazine are of the similar efficacy and safety for treating UC.Nevertheless,Xilei powder with low cost can provide a new choice for patients with UC.

关 键 词：锡类散 溃疡性结肠炎 META分析 

分 类 号：R574.62[医药卫生—消化系统]